Pyrazole compounds useful as protein kinase inhibitors

1. A compound of formula II:

or a pharmaceutically acceptable salt thereof, wherein:

Z 1 is CR 8 ;

R y is Z-R 3′ or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms, or R y and R 8 are taken together to form a fused, optionally substituted benzo ring;

Q is selected from —N(R 4 )—, —O—, —S—, or —CH(R 6 )—;

R 1 is T-(Ring D);

Ring D is a 6-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T-R 5 , or V-Z-R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;

T is a valence bond or a C 1-4 alkylidene chain, wherein when Q is —CH(R 6 )—, a methylene unit of said C 1-4 alkylidene chain is optionally replaced by —O—, —S—, —N(R 4 )—, —CO—, —CONH—, —NHCO—, —SO 2 —, —SO 2 NH—, —NHSO 2 —, —CO 2 —, —OC(O)—, —OC(O)NH—, or —NHCO 2 —;

Z is a C 1-4 alkylidene chain;

R 2 and R 2′ are independently selected from —R, -T-W—R 6 , or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2 ′ is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2′ is independently substituted by R 4 ;

R 3′ is selected from -halo, —OR, —C(═O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN,—S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC(═O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C═NN(R 4 ) 2 , C═N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, —OC(═O)N(R 7 ) 2 , or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;

each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;

each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;

each R 5 is independently selected from —R, halo, —OR, —C(═O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC(═O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C═NN(R 4 ) 2 , —C═N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC(═O)N(R 4 ) 2 ;

V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )C(O)—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 )═NN(R 6 )—, —C(R 6 )═N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 ) 2 N(R 6 )SO 2 N(R 6 )—, or —C(R 6 ) 2 N(R 6 )CON(R 6 )—;

W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 )═NN(R 6 )—, —C(R 6 )═N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 ) 2 N(R 6 )SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )CON(R 6 )—, or —CON(R 6 )—;

each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;

each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; and

R 8 is selected from —R, halo, —OR, —C(═O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC(═O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C═NN(R 4 ) 2 , —C═N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC(═O)N(R 4 ) 2 ; provided that when Q is —NH— and R y and R 8 are taken together, R 1 is other than pyrazol-3-yl or a bicyclic ring system containing said pyrazol-3-yl ring.

2. The compound according to claim 1 , wherein said compound has one or more features selected from the group consisting of:

(a) R y is Z-R 3′ or an optionally substituted group selected from C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, wherein Z is a methylene and R 3′ is —N(R 4 ) 2 , —OR, or an optionally substituted group selected from C 1-6 aliphatic, C 1-10 aryl a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;

(b) R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit;

(c) Ring D is a 6-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring; and

(d) R 2 is —R or -T-W—R 6 and R 2′ is hydrogen, or R 2 and R 2′ are taken together to form an optionally substituted benzo ring.

3. The compound according to claim 2 , wherein:

(a) R y is Z-R 3′ or an optionally substituted group selected from C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, wherein Z is a methylene and R 3′ is —N(R 4 ) 2 , —OR, or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;

(b) R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit;

(c) Ring D is a 6-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring; and

(d) R 2 is —R or -T-W—R 6 and R 2′ is hydrogen, or R 2 and R 2′ are taken together to form an optionally substituted benzo ring.

4. The compound according to claim 2 , wherein said compound has one or more features selected from the group consisting of:

(a) R y is an optionally substituted group selected from C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl;

(b) R 1 is T-(Ring D), wherein T is a valence bond, and Q is —S—, —NH—, or —CH2—;

(c) Ring D is a 6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring; and

(d) R 2 is —R and R 2′ is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.

5. The compound according to claim 4 , wherein:

(a) R y is an optionally substituted group selected from C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl;

(b) R 1 is T-(Ring D), wherein T is a valence bond, and Q is —S—, —NH—, or —CH 2 —;

(c) Ring D is a 6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring; and

(d) R 2 is —R and R 2′ is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.

6. The compound according to claim 4 , wherein said compound has one or more features selected from the group consisting of:

(a) R y is selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino, alkoxyalkyl, alkyl- or dialkylamino, alkyl- or dialkylaminoalkoxy, acetamido, optionally substituted phenyl, or methoxymethyl, or R y and R 8 are taken together to form a benzo ring;

(b) R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 6 membered aryl or heteroaryl ring, wherein Ring D is optionally substituted with one to two groups selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )SO 2 R, —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(F 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , and Q is —S— or —NH—; and

(c) R 2 is hydrogen or a substituted or unsubstituted C 1-6 aliphatic.

7. The compound according to claim 6 , wherein:

(a) R y is selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino, alkoxyalkyl, alkyl- or dialkylamino, alkyl- or dialkylaminoalkoxy, acetamido, optionally substituted phenyl, or methoxymethyl; or R y and R 8 are taken together to form benzo ring;

(b) R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 6 membered aryl or heteroaryl ring, wherein Ring D is optionally substituted with one to two groups selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )SO 2 R, —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , and Q is —S—or —NH—; and

(c) R 2 is hydrogen or a substituted or unsubstituted C 1-6 aliphatic.

8. A compound selected from the group consisting of:

6-Benzyl-N 4 -(1H-indazol-6-yl)-N 2 (5-methyl-1H-pyrazol-3-yl)-pyrimidine-2,4-diamine;

6-Methyl-N 2 -(5-methyl-1H-pyrazol-3-yl)-N 4 -pyridine-3-ylmethyl-pyrimidine-2,4-diamine;

N-(4-{2-(5-Methyl-1H-pyrazol-3-ylamino)-6-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-ylamino}-phenyl)-methanesulfonamide;

N 2 -(5-Cyclopropyl-1H-pyrazol-3-yl)-N 4 -(2-methoxy-ethyl)-6-(thiophen-2-ylmethylsulfanyl)-pyrimidine-2,4-diamine;

[4-(Benzothiazol-6-ylsulfanyl)-6-(3-dimethylamino-propoxy)-pyrimidine-2-yl]-(5-cyclopropyl-1H-pyrazol-3-yl)-amine;

N-(4-[2-{5-Cyclopropyl-1H-pyrazol-3-ylamino)-6-(1-methyl-piperidin-4-yloxy)-pyrimidin-4-ylsulfanyl]-phenyl}-acetamide;

N-{4-[2-(5-Methyl-1H-pyrazol-3-ylamino)-quinazolin-4-ylsulfanyl]-phenyl}-acetamide;

[4-(Benzothiazol-6-ylsulfanyl)-quinazolin-2-yl-(5-methyl1H-pyrazol-3-yl)-amine;

{4-[2-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-quinazolin-4-yloxy]-phenyl}-acetonitrile; (5-Cyclopropyl-1H-pyrazol-3-yl)-[4-(3-methoxy-benzyl)-quinazolin-2-yl]-amine; N 2 -(1H-Indazol-6-yl)-N 4 -pyridin-3-ylmethyl-quinazoline-2,4-diamine; and

(4-(Benzyloxy-quinazolin-2-yl-(1H-indazol-3-yl)-amine.

9. A composition comprising a compound according to anyone of claims 1 - 8 , arid a pharmaceutically acceptable carrier.

10. The composition according to claim 9 , further comprising an additional therapeutic agent.